Christian O'Donnell1, Alexander J Rodriguez1, Jai Madhok1, Husham Sharifi2, Hanjay Wang3, Connor G O'Brien4, Jack Boyd3, William Hiesinger3, Joe Hsu2, Charles C Hill5. 1. Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Stanford, CA. 2. Department of Medicine (Pulmonary, Allergy & Critical Care Medicine), Stanford University School of Medicine, Stanford, CA. 3. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA. 4. Department of Cardiovascular Medicine, University of California, San Francisco, CA. 5. Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Stanford, CA. Electronic address: chill1@stanford.edu.
Abstract
OBJECTIVE: To test the hypothesis that factor eight inhibitor bypassing activity (FEIBA) can be used to control bleeding following left ventricular assist device (LVAD) implantation without increasing the 14-day composite thrombotic outcome of pump thrombus, ischemic cerebrovascular accidents, pulmonary embolism, and deep venous thrombosis. DESIGN: Retrospective cohort study. SETTING: Academic hospital. PARTICIPANTS: Three hundred nineteen consecutive patients who underwent LVAD implantation (December 1, 2009 to December 30, 2018). INTERVENTION: FEIBA administered to control perioperative hemorrhage. MEASUREMENTS AND MAIN RESULTS: The 82 patients (25.7%) in the FEIBA cohort had more risk factors for perioperative hemorrhage, such as lower preoperative platelet count (169 ± 66 v 194 ± 68 × 103/mL, p = 0.004), prior cardiac surgery (36.6% v 21.9%, p = 0.008), and longer cardiopulmonary bypass (CPB) time (100.3 v 75.2 minutes, p = 0.001) than the 237 controls. After 16.6 units (95% CI: 14.3-18.9) of blood products were given, 992 units (95% CI: 821-1163) of FEIBA were required to control bleeding in the FEIBA cohort. Compared to the controls, there were no differences in the 14-day composite thrombotic outcome (11.0% v 7.6%, p = 0.343) or mortality rate (3.7% v 1.3%, p = 0.179). Multivariate logistical regression identified preoperative international normalized ratio (odds ratio [OR]: 1.30, 95% CI: 1.04-1.62) and CPB time (OR: 1.11, 95% CI: 1.02-1.20) as risk factors for 14-day thrombotic events, but FEIBA usage was not associated with an increased risk. CONCLUSIONS: In this retrospective cohort study, the use of FEIBA (∼1,000 units, ∼13 units/kg) to control perioperative hemorrhage following LVAD implantation was not associated with increases in mortality or composite thrombotic outcome.
OBJECTIVE: To test the hypothesis that factor eight inhibitor bypassing activity (FEIBA) can be used to control bleeding following left ventricular assist device (LVAD) implantation without increasing the 14-day composite thrombotic outcome of pump thrombus, ischemic cerebrovascular accidents, pulmonary embolism, and deep venous thrombosis. DESIGN: Retrospective cohort study. SETTING: Academic hospital. PARTICIPANTS: Three hundred nineteen consecutive patients who underwent LVAD implantation (December 1, 2009 to December 30, 2018). INTERVENTION: FEIBA administered to control perioperative hemorrhage. MEASUREMENTS AND MAIN RESULTS: The 82 patients (25.7%) in the FEIBA cohort had more risk factors for perioperative hemorrhage, such as lower preoperative platelet count (169 ± 66 v 194 ± 68 × 103/mL, p = 0.004), prior cardiac surgery (36.6% v 21.9%, p = 0.008), and longer cardiopulmonary bypass (CPB) time (100.3 v 75.2 minutes, p = 0.001) than the 237 controls. After 16.6 units (95% CI: 14.3-18.9) of blood products were given, 992 units (95% CI: 821-1163) of FEIBA were required to control bleeding in the FEIBA cohort. Compared to the controls, there were no differences in the 14-day composite thrombotic outcome (11.0% v 7.6%, p = 0.343) or mortality rate (3.7% v 1.3%, p = 0.179). Multivariate logistical regression identified preoperative international normalized ratio (odds ratio [OR]: 1.30, 95% CI: 1.04-1.62) and CPB time (OR: 1.11, 95% CI: 1.02-1.20) as risk factors for 14-day thrombotic events, but FEIBA usage was not associated with an increased risk. CONCLUSIONS: In this retrospective cohort study, the use of FEIBA (∼1,000 units, ∼13 units/kg) to control perioperative hemorrhage following LVAD implantation was not associated with increases in mortality or composite thrombotic outcome.
Authors: Matthew C Bunte; Eugene H Blackstone; Lucy Thuita; Jeff Fowler; Lee Joseph; Aska Ozaki; Randall C Starling; Nicholas G Smedira; Maria M Mountis Journal: J Am Coll Cardiol Date: 2013-08-28 Impact factor: 24.094
Authors: Ellen B Yin; Benedict Tan; Thuy Nguyen; Miguel Salazar; Kimberly Putney; Pramod Gupta; Jose I Suarez; Eric M Bershad Journal: Neurocrit Care Date: 2017-08 Impact factor: 3.210
Authors: Martin Ponschab; Giovanni Landoni; Giuseppe Biondi-Zoccai; Elena Bignami; Elena Frati; Davide Nicolotti; Fabrizio Monaco; Federico Pappalardo; Alberto Zangrillo Journal: J Cardiothorac Vasc Anesth Date: 2011-05-18 Impact factor: 2.628
Authors: Bryan A Whitson; Peter Eckman; Forum Kamdar; Alexandra Lacey; Sara J Shumway; Kenneth K Liao; Ranjit John Journal: Ann Thorac Surg Date: 2014-04-26 Impact factor: 4.330
Authors: Michael Fabbro; Prakash A Patel; Reney A Henderson; Daniel Bolliger; Kenichi A Tanaka; Michael A Mazzeffi Journal: J Cardiothorac Vasc Anesth Date: 2022-04-06 Impact factor: 2.894